You can buy or sell DRNA and other stocks, options, ETFs, and crypto commission-free!
Dicerna Pharmaceuticals, Inc. Common Stock, also called Dicerna Pharmaceuticals, is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. Read More The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.
52 Week High
52 Week Low
Simply Wall StMar 20
Will Dicerna Pharmaceuticals, Inc.’s (NASDAQ:DRNA) Earnings Grow In The Years Ahead?
The latest earnings update Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) released in December 2018 showed company earnings became less negative compared to the previous year’s level – great news for investors Below, I’ve presented key growth figures on how market analysts perceive Dicerna Pharmaceuticals’s earnings growth outlook over the next few years and whether the future looks brighter. I will be looking at earnings excluding extraordinary items to exclude one-off activities to get a better understanding...
Dicerna Pharmaceuticals Inc.
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -26.09% and -81.60%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Expected May 8, After Hours